Belvedere Trading’s Acadia Pharmaceuticals ACAD Stock Holding History

Belvedere Trading’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-14,000	Closed	-$263K	–	840
2023 Q1	$263K	Buy	+14,000	New	+$267K	﹤0.01%	257

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Belvedere Trading's ACAD Position: Q2 2023 in Review

Belvedere Trading sold out of Acadia Pharmaceuticals (ACAD) in Q2 2023, closing a stake of 1,166 shares — an estimated $21.9K sold.

Belvedere Trading first reported a position in ACAD in Q1 2023 and held it in 1 quarter. The position peaked at $21.9K in Q1 2023. 236 funds tracked by Wall St. Rank hold ACAD as of Q2 2023.

Belvedere Trading reported no remaining Acadia Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Belvedere Trading sold 1,166 Acadia Pharmaceuticals shares in Q2 2023, an estimated $21.9K.
Belvedere Trading first reported a position in Acadia Pharmaceuticals in Q1 2023 and held it in 1 quarter.
Belvedere Trading's Acadia Pharmaceuticals position peaked at $21.9K in Q1 2023.
236 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2023.

Based on Belvedere Trading's 13F filing for Q2 2023, filed 8 Aug 2023.